Literature DB >> 27405530

Thrombophilic DNA Mutations As Independent Risk Factors for Stroke and Avascular Necrosis in Sickle Cell Anemia.

S A Zimmerman1, T A Howard1, M R Whorton1, W F Rosse2, A H James3, R E Ware1.   

Abstract

Thrombosis may be important in the pathophysiology of certain complications of sickle cell anemia (SCA), including cerebrovascular accident (CVA, stroke) and avascular necrosis (AVN). No single laboratory or clinical parameter can accurately identify patients who will develop these thrombotic complications. We hypothesized that a subset of patients with SCA have genetic thrombophilic mutations that increase the risk of stroke or AVN. We examined nine known thrombophilic DNA polymorphisms in α-fibrinogen, β-fibrinogen, platelet glycoprotein IIIa, Factor VII, methylenetetra-hydrofolate reductase, plasminogen activator inhibitor-1, prothrombin, and Factor V genes in 101 African-American patients with SCA (27 CVA, 16 AVN). The allele frequency of thrombophilic mutations ranged from 0.0 (Prothrombin, Factor V) to 0.33 (α-fibrinogen). No mutation was significantly more common in patients with CVA or AVN than in patients without these complications. These nine thrombophilic mutations do not appear to be significant risk factors for the development of clinically overt CVA or AVN in SCA.

Entities:  

Keywords:  Avascular necrosis; Sickle cell anemia; Stroke; Thrombophilic mutations; Thrombosis

Year:  2001        PMID: 27405530     DOI: 10.1080/10245332.2001.11746590

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  2 in total

1.  Polymorphisms and avascular necrosis in patients with sickle cell disease - A systematic review.

Authors:  Márcio Passos Leandro; Natália Damasceno Almeida; Lara Santana Hocevar; Cloud Kennedy Couto de Sá; Amâncio José de Souza; Marcos Almeida Matos
Journal:  Rev Paul Pediatr       Date:  2022-05-11

2.  The molecular basis for the prothrombotic state in sickle cell disease.

Authors:  Arun S Shet; Maria A Lizarralde-Iragorri; Rakhi P Naik
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.